BAVA:VIE
Bavarian Nordic A/S
31,50 €
arrow_downward
-0,63%(-0,20) 1K
14-okt, 17:36:00 (GMT+2) · EUR
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoBAVA tikeri uchun statistika yaratilmoqda...
Ochish
31,66 €
Yuqori
31,74 €
Past
31,38 €
Bozor kapitali
2,77Â mlrd
Oʻrtacha hajm
17,00
Hajmi
0,00
52 haftalik eng yuqori
32,47 €
52 haftalik eng past
22,96 €
Xodimlar soni
2Â ming
Ochish
31,66 €
Yuqori
31,74 €
Past
31,38 €
Bozor kapitali
2,77Â mlrd
Oʻrtacha hajm
17,00
Hajmi
0,00
52 haftalik eng yuqori
32,47 €
52 haftalik eng past
22,96 €
Xodimlar soni
2Â ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Stock Titan
·
8 daqiqa oldin
Two governance gaps trigger a Nasdaq notice for Better Home & Finance (NASDAQ: BETR)
MarketWatch
·
3 daqiqa oldin
Why Dell’s stock was one of the S&P 500’s biggest laggards on Wednesday
TradingView
·
12 daqiqa oldin
Netcapital regains Nasdaq minimum bid price compliance
Seeking Alpha
·
2 soat oldin
Nasdaq tumbles 2%, and these 10 stocks have fueled the selloff
Profil
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
Bavarian Nordic A/S haqida
CEOPaul Chaplin
Xodimlar soni1,91Â ming
Asos solingan1-iyl, 1992
Bosh ofislar-
Sektor-
Veb-saytbavarian-nordic.com